Special Drug Use-Results Survey for Long-term Use of XEPLION TRI Aqueous Suspension for IM Injection 175 mg, 263 mg, 350 mg, and 525 mg Syringe
Not Applicable
- Conditions
- Schizophrenia
- Registration Number
- JPRN-UMIN000042033
- Lead Sponsor
- Janssen Pharma
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 990
Inclusion Criteria
Not provided
Exclusion Criteria
Patients not meeting Key inclusion criteria
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of adverse events related to QT prolongation (Includes relevant laboratory tests.), Concomitant use of oral antipsychotics, etc., Adherence (Treatment Compliance)
- Secondary Outcome Measures
Name Time Method